Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + carboplatin + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Sintilimab + carboplatin + nab-paclitaxel is a combination regimen used primarily in the treatment of advanced or locally advanced non-small cell lung cancer (NSCLC), including both squamous and non-squamous subtypes, as well as being investigated for use in gastric and gastroesophageal junction cancers. Sintilimab is a fully human IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2 to enhance T-cell mediated anti-tumor immunity. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis of rapidly dividing cells. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor that disrupts mitosis by stabilizing microtubules, preventing their depolymerization. The combination leverages immunotherapy with cytotoxic chemotherapy for synergistic anti-tumor effects[1][2][3][4][5].
- Brand names
- TyvytAbraxane
- Other names
- sintilimab + nab-paclitaxel + carboplatinsintilimab + albumin-bound paclitaxel + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on sintilimab + carboplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + carboplatin + nab-paclitaxel.